PC-SPES for the Treatment of Prostate Cancer?

References

• Greenlee R T, Hill-Harmon M B, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 1–3
   Web of Science ®Google Scholar
• Prostate Cancer (PDQ(r)). Treatment-Health Professionals. CancerNet., http://cancernet.nic.nih.gov/ Accessed November 13, 2001.
   Google Scholar
• Scher H I, Isaacs J T, Zelefsky M J, Scardino P T. Prostate cancer. Clinical Oncology, 2nd ed., M D Abeloff, J O Armitage, A S Lichter, J E Niederhuber. Churchill Livingstone, Inc., St. Louis, MO 2000
   Google Scholar
• O'Rourke M E. Genitourinary cancers. Oncology Nursing, 4th edition., S E Otto. Mosby, St. Louis, MO 2001
   Google Scholar
• Walsh P C, Partin A W. Family history facilitates the early diagnosis of prostate carcinoma. Cancer Nov 1, 1997; 80(9)1871–4
   PubMed Web of Science ®Google Scholar
• Ingles S A, Ross R K, Yu M C, Irvine R A, La Pera G, Haile R W, Coetzee G A. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997; 89: 166–170
   PubMed Web of Science ®Google Scholar
• Benowitz S. New Gene Finding May Yield Clues to Prostate Cancer Complexity. J Natl Cancer Inst 2001; 93: 344–345
   PubMed Web of Science ®Google Scholar
• Schulman C C, Ekane S, Zlotta A R. Nutrition and prostate cancer: evidence or suspicion?. Urol 2001; 58: 381–334
   Web of Science ®Google Scholar
• Kolesar J M, Goldspiel B R. Prostate cancer. Pharmacotherapy: A Patho-physiologic Approach, 4th ed. Appleton & Lange, Stamford, CT 1999
   Google Scholar
• Yip I, Heber D, Aronson W. Hormone refractory prostate cancer. Nutrition and prostate cancer. Urol Clin North Am 1999; 26(2)403–411
   PubMed Web of Science ®Google Scholar
• Chan J M, Stampfer M J, Giovannucci E, et al. Plasma insulin-like growth fac-tor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563
   PubMed Web of Science ®Google Scholar
• Drachenberg D E. Treatment of prostate cancer: watchful waiting, radical prostatectomy and cryoablation. Semin Surg Oncol 2000; 18: 37–44
   PubMed Web of Science ®Google Scholar
• DiPaola R S, Kumar P, Hait W N, Weiss R E. State-of-the-art prostate cancer treatment and research. A report from The Cancer Institute of New Jersey. N J Med 2001; 98(2)23–33
   PubMedGoogle Scholar
• Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Prostate Cancer Trialists' Collaborative Group. Lancet Apr. 29, 2000; 355(9214)1491–1498
   PubMed Web of Science ®Google Scholar
• Laufer M, Denmeade S R, Sinibaldi V J, Carducci M A, Eisenberger M A. Complete androgen blockade for prostate cancer: what went wrong?. J Urol 2000; 164: 3–9
   PubMed Web of Science ®Google Scholar
• Ades T, Gansler T, Miller M, Rosenthal D S. PC-SPES: current evidence and remaining questions. CA Can J Clin 2001; 51(3)199–204
   PubMed Web of Science ®Google Scholar
• Darzynkiewicz Z. Chinese herbal mixture PC SPES in treatment of prostate cancer (Review). Int J Oncol 2000; 17(4)729–736
   PubMed Web of Science ®Google Scholar
• Caldiroli M, Cova V, Lovisolo J A, Reali L, Bono A V. Antiandrogen withdrawal in the treatment of hormone-relapsed prostate cancer: single institutional experience. Eur Urol Jan, 2001; 39(Suppl 2)6–10
   PubMed Web of Science ®Google Scholar
• Pfeifer B L, Pirani J F, Hamann S R, Kleppel K F. PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer. BJU Int 2000; 85(4)481–485
   PubMed Web of Science ®Google Scholar
• Kao G D, Devine P. Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. Cancer 2000; 88(3)615–619
   PubMed Web of Science ®Google Scholar
• Nam R K, Fleshner N, Rakovitch E, et al. Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis. J Urol 1999; 161(5)1521–1524
   PubMed Web of Science ®Google Scholar
• Ukiya M, Akihisa T, Yasukawa K, Kasahara Y, Kimura Y, Koike K, Nikaido T, Takido M. Constituents of compositae plants. 2. Triterpene diols, triols, and their 3-O-fatty acid esters from edible chrysanthemum flower extract and their anti-inflammatory effects. J Agric Food Chem 2001; 49(7)3187–3197
   PubMed Web of Science ®Google Scholar
• Lu H, Uesaka T, Katoh O, Kyo E, Watanabe H. Prevention of the development of preneoplastic lesions, aberrant crypt foci, by a water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi) mycelia in male F344 rats. Oncol Rep 2001; 8(6)1341–1345
   PubMed Web of Science ®Google Scholar
• Wang S Y, Hsu M L, Hsu H C, Tzeng C H, Lee S S, Shiao M S, Ho C K. The anti-tumor effect of Ganoderma lucidum is medicated by cytokine released from activated macrophages and T lymphocytes. Int J Cancer 1997; 70(6)699–705
   PubMed Web of Science ®Google Scholar
• Wu T S, Shi L S, Kuo S C. Cytotoxicity of Ganoderma lucidum triterpens. J Nat Prod 2001; 64(8)1121–1122
   PubMed Web of Science ®Google Scholar
• Min B S, Gao J J, Nakamura N, Hattori M. Triterpenes from the spores of Ganoderma lucidum and their cytotoxicity against metha-A and LLC tumor cells. Chem Pharm Bull (Tokyo) 2000; 48(7)1026–1033
   PubMed Web of Science ®Google Scholar
• Chen X G, Han R. Effect of glycyrrhetinic acid on DNA damage and unscheduled DNA synthesis induced by benzo(a)pyrene. (Abstract) Yao Xue Xue Bao 1994; 29(10)725–729
   PubMedGoogle Scholar
• Shi G Z. Blockage of glyrrhiza uralensis and chelidonium majus in MNNG induced cancer and mutagenesis. (Abstract) Zhonghua Yu Fang Yi Xue Za Zhi 1992; 26(3)165–167
   PubMedGoogle Scholar
• Konoshima T, Takasaki M, Tokuda H. Anti-carcinogenic activity of the roots of Panax notoginseng. II. Biol Pharm Bull 1999; 22(1)1150–1152
   PubMed Web of Science ®Google Scholar
• Wang R L, Gao B L, Xiong M L, Mei Q D, Fan S K, Zuo Z K, Lang T L, Gao G Q, Ji Z C, Wei D C, et al. Potentiation by Rabdosia rubescens on chemotherapy of advanced esophageal carcinoma. Zhonghua Zhong Liu Za Zhi 1986; 84: 297–299
   Google Scholar
• Park H J, Lee Y W, Park H H, Lee Y S, Kwon I B, Yu J H. Induction of quinone reductase by a methanol extract of Scutellaria baicalensis and its flavonoids in murine Hepa 1c1c7 cells. Eur J Cancer Prev 1998; 7(6)465–571
   PubMed Web of Science ®Google Scholar
• Ishii K, Usui S, Sugimura Y, Yamamoto H, Yoshikawa K, Hiran K. Extract from Serenoa repens suppresses the invasion activity of human urological cancer cells by inhibiting urokinase-type plasminogen activator. Biol Pharm Bull 2001; 24(2)188–190
   PubMed Web of Science ®Google Scholar
• Iguchi K, Okumura N, Usui S, Sajiki H, Hirota K, Hirano K. Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells. Prostate 2001; 47(1)59–65
   PubMed Web of Science ®Google Scholar
• DiPaola R A, Zhang H, Lambert G H, et al. Clinical and biologic activity of an estrogenic herbal combination (PC SPES) in prostate cancer. N Engl J Med 1998; 339: 785–791
   PubMed Web of Science ®Google Scholar
• Geliebter J, Mittelman A, Tiwari R K. PC-SPES and prostate cancer. J Nutr 2001; 131((1))164S–166S
   PubMed Web of Science ®Google Scholar
• Hsieh T, Chen S S, Wang X, Wu J M. Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate cell LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES. Biochem and Molec Biol Internl 1997; 42(3)535–544
   PubMed Web of Science ®Google Scholar
• de la Taille A. Herbal therapy PC-SPES: in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J Urol 2000; 164(4)1229–1234
   PubMed Web of Science ®Google Scholar
• Halicka H D, Ardelt B, Juan G, et al. Apoptosis and cell cycle effects induced by extracts of the Chinese herbal preparation PC SPES. Int J Oncol 1997; 11: 437–448
   PubMed Web of Science ®Google Scholar
• Kubota T, Hisatake J, Hisatake Y, et al. PC-SPES: a unique inhibitor of proliferation of prostate cells in vitro and in vivo. Prostate 2000; 42(3)163–171
   PubMed Web of Science ®Google Scholar
• Hsieh T, Ng C, Chang C C, et al. Induction of apoptosis and down-regulation of bcl-6 in Mutu I cells treated with ethanolic extracts of the Chinese herbal supplement PC-SPES. Int J Oncol 1998; 13(6)1199–1202
   PubMed Web of Science ®Google Scholar
• Tiwari R K, Geliebter J, Garikapaty V PS, et al. Anti-tumor effects of PC-SPES, an herbal formulation in prostate cancer. Int J Oncol 1999; 14(4)713–719
   PubMed Web of Science ®Google Scholar
• Kameda H, Small E J, Reese D M. A phase II study of PC-SPES, an herbal compound, for the treatment of advanced prostate cancer (PCa). Proc Am Soc Clin Oncol 1999; 18: 320a
   Google Scholar
• de la Taille A. Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients. BJU Int 1999; 84(7)845–850
   PubMed Web of Science ®Google Scholar
• de la Taille A, Buttyan R, Hayek O, Bagiella E, Shabsigh A, Burchardt M, Burchardt T, Chopin D K, Katz A E. Herbal therapy PC-SPES: In vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J Urol 2000; 164: 1229–1234
   PubMed Web of Science ®Google Scholar
• Small E J, Frohlich M W, Bok R, et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 2000; 18(21)3595–3603
   PubMed Web of Science ®Google Scholar
• Oh W K, George D J, Hackmann K, et al. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology 2001; 57(1)122–126
   PubMed Web of Science ®Google Scholar
• Weinrobe M C, Montgomery B. Acquired bleeding diathesis in a patient taking PC-SPES. (Letter) N Engl J Med 2001; 345(16)1213–1214
   PubMed Web of Science ®Google Scholar
• Lock M, Loblaw A, Choo R, Imrie K. Disseminated intravascular coagulation and PC-SPES: a case report and literature review. Can J Urol 2001; 8(4)1326–1329
   PubMedGoogle Scholar
• de la Taille A. Role of herbal compounds (PC-SPES) in hormone-refractory prostate cancer: two case reports. J Altern Complement Med 2000; 6(5)449–451
   PubMed Web of Science ®Google Scholar
• Moyad M A, Pienta K J, Montie J E. Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease. Urol 1999; 54(2)319–323
   PubMed Web of Science ®Google Scholar
• Woo E W, Quinn M, Figg W D, Dahut W. The use of complementary and alternative medicine in prostate cancer patients. Oncol Issues 2000; 15(6)23–27
   Google Scholar
• Porterfield H. UsToo PC-SPES surveys: review of studies and update of previous survey results. Mol Urol 2000; 4(3)289–291, discussion 293
   PubMedGoogle Scholar
• A randomized phase II trial of sequential PC-SPES and DES, or DES followed by PC-SPES, in patients with androgen-independent prostate cancer. UCSF Cancer Ctr Clinical Trials, http://cc.ucsf.edu/trials Accessed 11/19/01.
   Google Scholar
• New NCCAM Research Centers Study Critical CAM-Cancer Questions. NCCAM Newsletter 2001; 5, Winter
   Google Scholar